Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.
Sponsor: University Ghent
Summary
The goal of this interventional, prospective research on human bodily material is to discover new, cancer-specific molecular structures (i.e. glycopeptides) within surgically removed, estrogen receptor positive breast cancer tumors. The main goal it aims to achieve is: To discover tumor-specific targets, that allow the use of very potent immunotherapeutic drugs as treatment for solid tumors, such as estrogen receptor positive breast cancer. These new targets are very specific for cancer cells, meaning that virtually no healthy cells should be attacked by the treatment, resulting in less side effects. Participants will undergo standard of care treatment, comprising surgical removal of the breast tumor. Part of these tissues will be used for this clinical research.
Official title: Tn-Miner: Technology for the Discovery of Tumor-specific Glycopeptide Immunotherapy Targets.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2024-09-25
Completion Date
2025-12-31
Last Updated
2025-08-29
Healthy Volunteers
No
Conditions
Interventions
Tumor resection
As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
Locations (2)
AZ Maria Middelares
Ghent, East-Flanders, Belgium
University Hospital Ghent
Ghent, East-Flanders, Belgium